Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LHCGR | P22888 | 11/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | HHAT | Q5VTY9 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23947745 | 0.83 | LHCGR (0.48) | LHCGRCNR1HHATNPSR1 | |
| SCHEMBL23947757 | 0.82 | HHAT (0.39) | LHCGRHHAT | |
| SCHEMBL29763655 | 0.82 | HHAT (0.39) | LHCGRHHAT | |
| SCHEMBL8176067 | 0.69 | LHCGR (0.59) | POLBLHCGRCNR1MAPK1NPSR1 | |
| SCHEMBL7891790 | 0.69 | POLB (0.69) | POLBLHCGRCNR1HHATMAPK1 | |
| SCHEMBL7889844 | 0.69 | LHCGR (0.69) | POLBLHCGRCNR1MAPK1NPSR1 | |
| Hydrochloric Acid SCHEMBL7886002 | 0.69 | LHCGR (0.58) | POLBLHCGRCNR1MAPK1NPSR1 | |
| SCHEMBL23947759 | 0.68 | HHAT (0.40) | LHCGRHHAT | |
| SCHEMBL29763691 | 0.68 | HHAT (0.40) | LHCGRHHAT | |
| SCHEMBL23947761 | 0.68 | LHCGR (0.50) | LHCGRHHATNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533339-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240173291-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| US-11877999-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-23 | — | — | US | disclosed |
| US-11628158-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| WO-2021212010-A2 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | POLB 30/4885LHCGR 3029/4885CNR1 4715/4885 |
| US-11877999-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | TP53, EIF2AK2, POLI | POLB 30/4885LHCGR 3029/4885CNR1 4715/4885 |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | POLB 30/4885LHCGR 3029/4885CNR1 4715/4885 |
| US-12533339-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | CCND3, CCND1, TPD52L2 | POLB 424/4885LHCGR 630/4885CNR1 508/4885 |
| US-20240173291-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | POLB 30/4885LHCGR 3029/4885CNR1 4715/4885 |
| US-11628158-B2 | Small molecule antiviral drug treatment for human papillomavirus infections | TP53, EIF2AK2, POLI | POLB 30/4885LHCGR 3029/4885CNR1 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.